

Appendix S1

In the FOLFOX6 regimen, oxaliplatin and leucovorin were given via i.v. infusion at doses of 100 and 200 mg/m² respectively on day 1, followed by administration of 5-FU as i.v. bolus at a dose of 400 mg/m² on day 1, then 2,400 mg/m² over 46-48 h.

In the mFOLFOX6 regimen, oxaliplatin and leucovorin were given via i.v. infusion at doses of 85 and 400 mg/m² respectively on day 1, followed by administration of 5-FU as i.v. bolus at a dose of 400 mg/m² on day 1, then 2,400 mg/m² over 46-48 h.

In the FOLFIRI regimen, Irinotecan and leucovorin were given via i.v. infusion at doses of 180 and 100 mg/m²

respectively on day 1, followed by administration of 5-FU as i.v. bolus at a dose of 400 mg/m² on day 1, then 2,400 mg/m² over 46-48 h.

In the FOLFOXIRI regimen, oxaliplatin, Irinotecan and leucovorin were given via i.v. infusion at doses of 85, 165 and 400 mg/m² respectively on day 1, followed by administration via i.v. of 5-FU at doses of 3,200 mg/m² over 46-48 h.

For patients receiving oral capecitabine monotherapy, the dose was 1,250 mg/m², twice daily from day 1 to day 14 followed by a 7-day rest period.

For patients receiving capecitabine in combination with oxaliplatin, oxaliplatin was given as a 2-h i.v. infusion at a dose of 130 mg/m² on day 1 and oral capecitabine given at 1,000 mg/m² twice daily from day 1 to day 14.